A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2. Inhibitor. Diabetes Metab J. 2014; 38: 261–273. 3. Micromedex® 2.0: Dapaglifolzin, Canagliflozin, ...
確定! 回上一頁